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Abstract
Background: Bed-ridden state, dysphagia, altered mental state, or respiratory muscle weakness are common in
neurologic patients and increase the risk of pneumonia. The major causes of pneumonia in neurologic patients may
differ from those in the general population, resulting in a different pathogen distribution. We investigated the
trends of pathogen distribution in culture-positive pneumonia in hospitalized neurologic patients and the related
antibiotic resistance in those with hospital-acquired pneumonia (HAP).
Methods: A retrospective study was performed at Seoul National University Hospital, South Korea. Patients admitted to
the Department of Neurology with a positive respiratory specimen culture between 2007 and 2016 were included.
Pneumonia events in patients were screened by chronologically associating the date of respiratory specimen
acquisition for culture studies and the date of antibiotics administration. Subgroup analyses regarding multidrug
resistance in HAP were performed in different pneumonia categories, by presence of ≥1 risk factor and by time
period (first half vs. second half of study period). Microbial resistance profiles of isolates from patients with
pneumonia were analyzed.
Results: We identified 351 pneumonia cases in 227 patients involving 36 different pathogens. 232 cases were
HAP, of which 70 cases were intensive care unit (ICU)-HAP. The leading pathogens were Stapylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Streptococcus pneumoniae, and Enterobacter
aerogenes, which were isolated in 133 (37.9%), 72 (20.5%), 55 (15.7%), 44 (12.5%), 33 (9.4%), and 27 (7.7%) cases,
respectively. Cases with HAP showed a higher proportion of P. aeruginosa and a lower proportion of S. pneumoniae
(both, p < 0.05) than those with non-HAP. ICU-HAP isolates showed a higher multidrug resistance (MDR) rate than
non-ICU-HAP isolates (p < 0.005) in those with ≥1 MDR risk factor. Non-susceptibility to imipenem (p < 0.0005),
piperacillin-tazobactam (p < 0.001), cefepime (p < 0.005), and trimethoprim-sulfamethoxazole (p < 0.05) in Gram-negative
pathogens increased over time in both ICU and non-ICU settings.
Conclusions: S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, S. pneumoniae, and E. aerogenes were the leading
isolates in culture-positive pneumonia in hospitalized neurologic patients. Antimicrobial resistance of Gram-negative
pathogens in neurologic patients with culture-positive HAP has recently increased.
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Background
Nosocomial infection results in higher mortality, an ex-
tended hospitalization period, and escalated healthcare
costs [1–3]. Nosocomial infection, especially urinary
tract infection and pneumonia, has been estimated to
develop in one-third of stroke patients, who comprise
the majority of neurologic patients [4, 5]. Hospitalized
patients with neurologic diseases are especially prone to
pneumonia, in which a bed-ridden state, dysphagia, an
altered mental state, or mechanical ventilation due to re-
spiratory muscle weakness can all increase its risk [6].
Early empiric coverage for possible pathogens of
hospital-acquired pneumonia (HAP) is crucial to improve
the prognosis, which requires knowledge of recent prevalence
of antibiotic-resistant pathogens such as methicillin-resistant
Staphylococcus aureus and multidrug-resistant nonfer-
menters [7, 8]. The distribution of pathogens causing
HAP and their antibiotic resistance profiles differ accord-
ing to region and individual circumstances (e.g. intensive
care unit (ICU) setting vs. non-ICU setting, local micro-
bial flora) [8–10]. Treatment guidelines have been pro-
posed in both Western and Asian countries [10, 11].
However, neurologic patients comprise only a limited
number within most data. Therefore, we investigated
trends in microbial etiology of pneumonia in hospitalized
patients with neurologic diseases, along with changes in
the antibiotic resistance profiles of common pathogens.
Methods
Patient screening and inclusion
Data were retrospectively reviewed via the electronic med-
ical record (EMR) system of Seoul National University
Hospital (SNUH), South Korea. Data of patients who were
admitted to the Department of Neurology from January 1,
2007 to December 31, 2016 were collected.
Patients with at least one positive respiratory specimen
culture and/or blood culture result were included. Re-
spiratory specimens with a Grams-stain result showing
≥25 squamous epithelial cells per low-power field were
considered as inadequate samples and were excluded.
Respiratory specimens were collected using upper re-
spiratory tract suction, transtracheal aspiration (through
the tracheostomy site), endotracheal aspiration (through
the endotracheal tube), bronchoalveolar lavage, or as ex-
pectorated sputum.
To screen events of infectious diseases, we selected re-
spiratory cultures chronologically related to the adminis-
tration of antibiotic agents. Specifically, those with a
history of at least 4 days of antibiotic administration and
those whose antibiotics were administrated within 3 days
of the first blood and/or respiratory specimen culture
were included. Patients with a history of antibiotic ad-
ministration ≤3 days were excluded because short anti-
biotic administration periods were mostly observed in
those with causes other than pneumonia, such as aspir-
ation pneumonitis. Patient data were anonymized to
protect patient privacy.
Definitions
Pneumonia was defined as fever and/or leukocytosis with
either clinical (rales or new onset of purulent sputum) or
radiological (new or progressive infiltrate, consolidation,
cavitation, or pleural effusion) evidence of pneumonia.
EMR was reviewed to exclude patients without evidence
of pneumonia. Clinically or radiologically ambiguous cases
were only included if the primary physician and a con-
sulted expert in infectious diseases both agreed upon the
case as pneumonia. Cultured microorganisms were con-
sidered as pathogens if a culture was obtained under the
diagnosis of pneumonia, but were considered as colo-
nizers or a contamination if the patient clinically improved
without an adequate microbial therapy (Fig. 1).
Cases of pneumonia were classified by the period of oc-
currence (early or late), the location of infection (communi-
ty-acquired, health-care-associated, or hospital-acquired)
with hospital-acquired pneumonia further categorized to
ICU-related or non-related, multi-drug resistance (MDR)
of the pathogen, and the presence of any risk factor
of multi-drug resistant pathogen infection in hospital-
acquired pneumonia.
The first half of the study period (from January 1, 2007 to
December 31, 2011) was defined as the early period and
the second half of the study period (from January 1, 2012
to December 31, 2016) was defined as the late period.
Hospital acquired-pneumonia was defined as an onset
of pneumonia more than 48 h after admission [10, 12].
HAP was further subclassified into intensive care unit
(ICU)-HAP or non-ICU-HAP depending on the location
of the patient at the onset of pneumonia. Patients with
HAP were classified as ICU-HAP if the first signs of pneu-
monia were noted after 48 h in intensive care. Pneumonia
occurring in the first 48 h after ICU discharge were also
categorized as ICU-HAP. Otherwise, the patients were
classified as non-ICU-HAP. Cases were defined as
healthcare-associated pneumonia (HCAP) if the onset of
pneumonia preceded or was within 48 h of admission and
the patient had a separate history of hospitalization ≥2
days (either at SNUH or at other hospitals) within the pre-
vious 90 days, or had residence in a nursing home or ex-
tended care facility [12]. Otherwise, cases were defined as
community-acquired pneumonia (CAP).
MDR was defined for the most common pathogens of
pneumonia from our data. We followed definitions pro-
posed by the European Centre for Disease Prevention
and Control for defining MDR of S. aureus, Klebsiella
pneumoniae (K. pneumoniae), Acinetobacter baumannii
(A. baumannii), Pseudomonas aeruginosa (P. aeruginosa),
and Enterobacter aerogenes (E. aerogenes) [13]. In short,
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non-susceptibility to ≥1 agent in ≥3 antimicrobial categories
was defined as MDR. S. aureus was also defined as multi-
drug resistant if identified as methicillin-resistant. MDR of
Streptococcus pneumoniae (S. pneumoniae) was defined as
resistance to ≥2 classes of the following antimicrobial
agents: penicillin, ceftriaxone, erythromycin, levofloxacin,
tetracycline, and trimethoprim-sulfamethoxazole [14].
Antibiotic susceptibility results were reported as qualitative
results (i.e. resistant, intermediate, or susceptible) with/
without quantitative results (minimum inhibitory concen-
tration). All susceptibility results were tested using the
guidelines of Clinical & Laboratory Standards Institute
(CLSI).
Risk factors for MDR pathogens in HAP were esti-
mated following the American Thoracic Society (2005)
guidelines [12]. Specifically, late onset (≥5 days after
current admission), antimicrobial therapy in the preced-
ing 90 days, hospitalization ≥2 days in the preceding 90
days, residence in a nursing home or an extended care
facility were regarded as risk factors for MDR.
Statistical analysis
A Fisher’s exact test was used to compare categorical
variables. Proportional changes in individual antibiotic
susceptibilities or MDR of common Gram-negative bac-
teria throughout the study periods were compared using
the Cochran–Mantel–Haenszel test. All probabilities
were two-tailed and a p-value of less than 0.05 was con-
sidered to be statistically significant. R (version 3.4.4)
was used to perform the analysis.
Results
Frequency of each pathogen
Of 5756 positive respiratory specimen culture results and
1427 positive blood culture results involving 1417 patients
(F:M= 564:853), 3071 respiratory specimen culture results
and 638 blood culture results from 996 patients were
associated with a ≥ 4 days antibiotics-administration. After
reviewing the EMR and radiological data, 351 pneumonia
cases involving 227 patients (age, 62.9 ± 18.9 years;
F:M = 81:196) were finally included. Eighty-five cases
(24%) had multiple pathogens (75 cases with 2 pathogens
and 10 cases with 3 pathogens) (Fig. 2). The majority of
cases were HAP (70 and 162 ICU- and non-ICU-HAP, re-
spectively), with 65 HCAP cases and 54 CAP cases.
We identified 36 different pathogens. The most fre-
quent pathogens in total were S. aureus, K. pneumoniae,
A. baumannii, P. aeruginosa, S. pneumoniae, and E.
aerogenes, which were isolated in 133 (37.9%), 72
(20.5%), 55 (15.7%), 44 (12.5%), 33 (9.4%), and 27 (7.7%)
cases, respectively (Table 1, Additional file 1: Figures S1
and S2). There was an overall increment in the propor-
tion of non-ICU-HAP cases. In the 232 cases of HAP, S.
aureus (38.8%), K. pneumoniae (22.4%), A. baumannii
(18.5%), P. aeruginosa (11.6%), E. aerogenes (8.6%), and
S. pneumoniae (6.9%) were the most frequent pathogens.
A. baumannii was more frequent and S. pneumoniae
was less frequent in HAP cases than in non-HAP cases
(both, p < 0.05). Moreover, among the HAPs, the fre-
quency of each pathogen differed according to whether a
patient had a risk factor for MDR. In 199 patients with
≥1 risk factor, S. aureus (38.2%), K. pneumoniae (21.6%),
Fig. 1 Patient selection flow chart. Of 5756 and 1427 positive respiratory specimen cultures and blood cultures, respectively, 372 respiratory
cultures and 34 blood cultures involving 227 patients and 351 pneumonia cases were finally included
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A. baumannii (20.6%), and P. aeruginosa (13.6%) were
the leading isolates, while in 33 patients without a risk
factor, S. aureus (42.4%), K. pneumoniae (27.3%), S.
pneumoniae (18.2%), and A. baumannii (6.1%) were the
leading isolates (Fig. 3).
MDR in HAP cases
MDR was more prevalent in HAP cases with ≥1 MDR
risk factor, among which ICU-HAP cases more fre-
quently showed MDR than non-ICU-HAP cases. In 265
isolates from 204 HAP cases involving the 6 most fre-
quent pathogens, the frequency of MDR was evaluated
(Additional file 1: Table S1). Isolates from cases with at
least one MDR risk factor showed a significantly higher
rate of MDR compared to those from cases without any
MDR risk factor (p < 0.001). Specifically, 7 (19.4%) out of
36 isolates from 26 cases without any MDR risk factor
showed MDR, while 141 (61.6%) out of 229 isolates from
178 cases with ≥1 MDR risk factor showed MDR. MDR
was seen in 58 (75.3%) of 77 isolates from ICU-HAP
cases with ≥1 MDR risk factor, while 83 (54.6%) of 152
isolates from non-ICU-HAP cases with ≥1 MDR risk
factor showed MDR (p < 0.005).
The proportion of MDR of common Gram-positive bac-
teria (i.e. S. aureus and S. pneumoniae) was compared be-
tween the early and late years of the study period. S.
aureus showed MDR in 67 of the 90 cases of HAP with S.
aureus infection (Additional file 1: Table S2). However,
there was no statistically significant change in the
frequency of multidrug-resistant S. aureus in the early and
late study periods (p = 0.834). Thirteen (86.7%) of 15 cases
and 14 (63.6%) of 22 cases were due to
multidrug-resistant S. aureus in the early years in the ICU
and non-ICU settings, respectively, while 15 (88.2%) of 17
cases and 25 (69.4%) of 36 cases in the late years showed
MDR, respectively. All multidrug-resistant S. aureus iso-
lates showed resistance to oxacillin. Only one case, which
occurred in 2015 from a non-ICU setting, showed an
intermediate susceptibility result to vancomycin. Of the 16
HAP cases (6 in the early periods and 10 in the late pe-
riods) due to S. pneumoniae, 50% of cases were due to
multidrug-resistant S. pneumoniae in each period.
The most common Gram-negative bacteria in HAP
were K. pneumoniae, A. baumannii, P. aeruginosa, and
E. aerogenes. The number of HAP events due to the
common Gram-negative bacteria in the early and late
Fig. 2 Number of culture-positive pneumonia cases and isolated pathogens per year. Eighty-five cases (24%) had multiple pathogens (75 cases
with 2 pathogens and 10 cases with 3 pathogens)
Table 1 Frequency of isolated pathogens in HAP and non-HAP
pneumonia cases from 2007 to 2016
HAP Non-HAP Total
ICU Non-ICU
S. aureus 32 (45.7%) 58 (35.8%) 43 (36.1%) 133 (37.9%)
K. pneumoniae 9 (12.9%) 43 (26.5%) 20 (16.8%) 72 (20.5%)
A. baumannii* 22 (31.4%) 21 (13.0%) 12 (10.1%) 55 (15.7%)
P. aeruginosa 3 (4.3%) 24 (14.8%) 17 (14.3%) 44 (12.5%)
S. pneumoniae* 1 (1.4%) 15 (9.3%) 17 (14.3%) 33 (9.4%)
E. aerogenes 9 (12.9%) 11 (6.8%) 7 (5.9%) 27 (7.7%)
Others 10 (14.3%) 34 (21.0%) 38 (31.9%) 82 (23.4%)
total 70 (100%) 162 (100%) 119 (100%) 351 (100%)
A. baumannii was more frequent and S. pneumoniae was less frequent in HAP
cases than in non-HAP cases. *p < 0.05
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periods were 47 and 84, respectively. The frequency of
MDR of these pathogens did not significantly differ be-
tween the early and late study periods (Table 2).
Trends in antibiotic susceptibility of gram-negative bacteria
When we compared the resistance to each antibiotic agent
of the common Gram-negative bacteria in the early and
late study periods, an overall increasing trend in the
proportion of cases with pathogens showing non-suscepti-
bility (i.e. resistant or intermediate results) to each anti-
biotic agent was seen (Fig. 4). Antibiotic susceptibilities to
ciprofloxacin, ceftazidime, cefepime, and imipenem were tested
in all 131 cases while susceptibilities to piperacillin-tazobactam,
amikacin, trimethoprim-sulfamethoxazole, and colistin
were tested in 123, 111, 107, and 64 cases, respectively.
Increasing non-susceptibility to various antibiotic agents
was seen in both the ICU and non-ICU settings.
Specifically, non-susceptibility to imipenem (p < 0.0005),
piperacillin-tazobactam (p < 0.001), cefepime (p < 0.005),
and trimethoprim-sulfamethoxazole (p < 0.05) increased
in both the ICU and non-ICU settings, while non-suscep-
tibility to ciprofloxacin (p < 0.05) and ceftazidime (p <
0.01) increased in non-ICU settings but remained high in
ICU settings. The proportion of non-susceptibility to ami-
kacin (6.7, 12.0, 15.4, and 16.7% in the non-ICU early
period, non-ICU late period, ICU early period, and ICU
late period, respectively) and colistin (0% in non-ICU set-
ting of both periods and ICU early period, and 5.3% in the
ICU late period) remained low throughout the years in
both settings. Trends in antibiotic resistance to common
Gram-positive bacteria, S. aureus and S. pneumoniae, were
separately evaluated because the types of antimicrobial
susceptibility tests performed were different in each bac-
teria (Additional file 1: Figures S2-S4).
Discussion
We analyzed the distribution of pathogens of hospital-
ized patients with culture-positive pneumonia, pathogen
changes in relation to MDR, and the susceptibility to in-
dividual antibiotic agents in a single center. The most
frequent pathogens were S. aureus, followed by K. pneu-
moniae, A. baumannii, P. aeruginosa, and E. aerogenes.
P. aeruginosa was more frequent and S. pneumoniae
was less frequent in HAP cases than in non-HAP cases.
Fig. 3 Proportion of each pathogen in HAP cases with or without MDR risk factors. The frequency of each pathogen differed by whether each
case had a risk factor for MDR. In those with ≥1 risk factor, P. aeruginosa were more frequent and S. pneumoniae was less frequent. *p < 0.05
Table 2 Frequency of MDR and non-MDR Gram-negative
pathogens in the early and late periods of the study





A. baumannii Early 7 2 1
Late 28 6
K. pneumoniae Early 7 9 1
Late 15 21
P. aeruginosa Early 1 13 0.076
Late 5 8
E. aerogenes Early 1 8 1
Late 1 10
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In the presence of at least one MDR risk factor, MDR was
more frequent in ICU settings than in non-ICU settings.
Although there was no significant change in the frequency
of MDR in any pathogen throughout the study period,
non-susceptibility to individual antimicrobial agents in
Gram-negative bacteria significantly increased.
Compared to previous studies, our study showed a
higher proportion of K. pneumoniae in isolates from
culture-positive HAP. A study from the SENTRY program
showed that, in the United States and Europe, S. aureus
(range, 23.0–36.2%) and P. aeruginosa (range, 19.7–20.8%)
were the predominant isolates in HAP while K. pneumo-
niae and A. baumannii accounted for a lower proportion
(range, 8.5–10.1% and range, 4.8 to 5.6%, respectively) [15].
Another prospective surveillance study in Asian countries
showed S. aureus was the predominant pathogen in HAP
in South Korea and Singapore (range, 26.7–30.7%), while
K. pneumoniae (range, 25.0–30.6%), A. baumannii (range,
16.2–27.2%), and P. aeruginosa (range, 10.0–21.9%) were
the predominant pathogens in other countries [8]. Interest-
ingly, a recently published systematic review of pneumonia
complicating stroke showed a high proportion (21.8%) of
K. pneumoniae from culture-positive pneumonia [16].
Although the proportion of MDR in each Gram-negative
pathogen did not significantly increase throughout the
study period, the proportion of non-susceptibility to several
antibiotic agents in Gram-negative pathogens were signifi-
cantly increased. In our study, there was an increase in
non-susceptibility to imipenem, piperacillin-tazobactam,
cefepime, ciprofloxacin, and ceftazidime, which are
antibiotics targeting Gram-negative bacteria in HAP with
MDR risk factors, suggesting low antimicrobial effects in
cases where these antibiotics are empirically administered.
Numerous studies have shown a recent increasing trend in
antimicrobial resistance in Gram-negative bacteria [17–
20]. Data from the Surveillance Network showed
non-susceptibility to carbapenems in A. baumannii in-
creased from 22 to 52% from 2002 to 2008. Similarly,
non-susceptibility to carbapenems in A. baumannii in our
study increased from 55.6 to 83.8%, which is strikingly high
compared to studies published in recent years [8, 15, 21].
Our study consisted of data across a 10-year study
period involving clinical and/or radiologically defined
cases of pneumonia. The response to antibiotics was
considered when making etiologic diagnoses so as not to
mistake commensal bacteria as pathogens. Our study
shows a definite trend of increasing resistance to com-
monly used antibiotics in Gram-negative pathogens, and
a higher prevalence of MDR pathogens in HAP in ICU
settings, and in patients with MDR risk factors.
Our study has some limitations. The cases included in
our study consisted of culture-positive pneumonias only.
A study comparing the outcome of ICU-acquired pneu-
monia showed negative microbiologic findings were as-
sociated with a shorter duration of antimicrobial
treatment and better survival [22]. Since our study did
not include culture-negative pneumonias, it may show
results with a higher proportion of pathogens with MDR
or higher virulence. The screening method using the
number of days of antibiotic administration to detect a
Fig. 4 Trends of susceptibility to each antibiotic agent in the early (2007–2011) and late (2012–2016) periods of the study. Non-susceptibility to
imipenem, piperacillin-tazobactam, cefepime, and trimethoprim-sulfamethoxazole increased in both ICU and non-ICU settings, while non-susceptibility
to ciprofloxacin and ceftazidime increased in non-ICU settings but remained high in ICU settings. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001
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pneumonia event may also have impact on the results.
Although most events with a short antibiotic administra-
tion period would be those without a definite evidence
of infection such as aspiration pneumonitis, there is also
a possibility of short administration due to early mortal-
ity. This may have resulted in excluding critically-ill pa-
tients close (within 3 days) to death from our study.
Overall, our study excluded culture-negative pneumonia,
which is common in clinical practice, and may have also
excluded cases with positive culture results due to the
limitations of our screening methods. Regarding this
study was done in culture positive pneumonia patients
who have had antibiotic therapy for 4 days or more, ex-
trapolating the results to other populations is hampered,
and they cannot be used to guide empirical therapy in
the days before the culture result is known. Changes in
the MIC breakpoints in the CLSI guidelines should be
accounted for the rise of antimicrobial resistance to
some antibiotics. Recently, CLSI lowered the breakpoints
for several beta-lactam antibiotics, potentially leading
more isolates reported as intermediate or resistant to the
tested antibiotics [23, 24]. Our study was performed in a
single neurologic center, which, considering that hospital
personnel may act as a vehicle of pathogen dissemin-
ation, could have increased the frequency of specific
pathogens, resulting in a skewed distribution of patho-
gens. A multi-centered study is could reduce such over-
representation. Neurologic patients are more prone to
difficulty swallowing, leading to a higher chance of aspir-
ation pneumonia, which may explain the high propor-
tion of K. pneumoniae in the non-ICU setting in our
study compared to the study by Chung et al. [8].
Conclusion
S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa,
and E. aerogenes were the most prevalent pathogens
identified in our study. The proportions of each patho-
gen differed according to whether the patient had an
MDR risk factor and whether infection took place in the
ICU or not. Resistance to piperacillin-tazobactam and
carbapenems in HAP due to Gram-negative pathogens
has recently increased, especially in ICU settings.
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